New treatments for metabolic diseases in cystic fibrosis patients
Novel Selective SGLT-1 Inhibitors for Adjunctive Therapy for Cystic Fibrosis Associated Metabolic Diseases
This study is looking at new medications that could help people with cystic fibrosis manage diabetes and liver issues by targeting specific glucose transporters, especially for those who have had worsening health after starting a treatment called Trikafta.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Genetobe INC. NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11006091 on NIH RePORTER |
What this research studies
This research focuses on developing new medications that target specific glucose transporters to help manage metabolic diseases associated with cystic fibrosis, particularly CF-related diabetes and liver disease. The approach involves creating selective inhibitors of the sodium-dependent glucose cotransporter 1 (SGLT1), which may help improve metabolic health in patients who have experienced worsening conditions after starting Trikafta, a recently approved cystic fibrosis treatment. The research utilizes a novel rabbit model that mimics the metabolic disorders seen in cystic fibrosis patients, allowing for targeted testing of these new compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cystic fibrosis who are experiencing metabolic complications, particularly those related to diabetes and liver disease.
Not a fit: Patients without cystic fibrosis or those who do not have metabolic complications associated with the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of metabolic diseases in cystic fibrosis patients, enhancing their overall health and quality of life.
How similar studies have performed: While the approach of targeting SGLT1 is relatively novel, there have been successes with other SGLT inhibitors in treating diabetes, suggesting potential for this new line of therapy.
Where this research is happening
Ann Arbor, United States
- Genetobe INC. — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Xu, Jie — Genetobe INC.
- Study coordinator: Xu, Jie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.